TY - JOUR
T1 - Identification of novel conserved Ixodes vaccine candidates; a promising role for non-secreted salivary gland proteins
AU - Trentelman, Jos J. A.
AU - de Vogel, Fons A.
AU - Colstrup, Emil
AU - Sima, Radek
AU - Coumou, Jeroen
AU - Koetsveld, Joris
AU - Klouwens, Michelle J.
AU - Nayak, Abhijeet
AU - Ersoz, Jasmin
AU - Barriales, Diego
AU - Tomás-Cortázar, Julen
AU - Narasimhan, Sukanya
AU - Hajdusek, Ondrej
AU - Anguita, Juan
AU - Hovius, Joppe W.
N1 - Funding Information: We would like to thank Danielle van Hout, Leticia Sampedro and Miguel A Pascual-Itoiz for their technical assistance. This project has received funding from the European Union’s Seventh Programme for research, technological development and demonstration under grant agreement No. 602272 of which JWH was the scientific coordinator. This work was also supported by a “Vidi” grant (09150171910024) from JWH received from The Netherlands Organisation for health research and development (ZonMw). RS and OH were supported from the grant Centre for Research of Pathogenicity and Virulence of Parasites (no. CZ.02.1.01/0.0/0.0/16_019/ 0000759), funded by the European Regional Development Fund (ERDF) and Ministry of Education, Youth, and Sport, Czech Republic (MEYS). R.S. was supported by the Ministry of Health of the Czech Republic, grant no. NU20-05-00396, and by the Czech Science Foundation grant no. 22-30920S. The following reagents were provided by Centers for Disease Control and Prevention for distribution by BEI Resources, NIAID, NIH: I. ricinus Nymph (Live), NR-44118 and I. ricinus Adult (Live), NR-42511. Funding Information: We would like to thank Danielle van Hout, Leticia Sampedro and Miguel A Pascual-Itoiz for their technical assistance. This project has received funding from the European Union's Seventh Programme for research, technological development and demonstration under grant agreement No. 602272 of which JWH was the scientific coordinator. This work was also supported by a “Vidi” grant (09150171910024) from JWH received from The Netherlands Organisation for health research and development (ZonMw). RS and OH were supported from the grant Centre for Research of Pathogenicity and Virulence of Parasites (no. CZ.02.1.01/0.0/0.0/16_019/ 0000759), funded by the European Regional Development Fund (ERDF) and Ministry of Education, Youth, and Sport, Czech Republic (MEYS). R.S. was supported by the Ministry of Health of the Czech Republic, grant no. NU20-05-00396, and by the Czech Science Foundation grant no. 22-30920S. The following reagents were provided by Centers for Disease Control and Prevention for distribution by BEI Resources, NIAID, NIH: I. ricinus Nymph (Live), NR-44118 and I. ricinus Adult (Live), NR-42511. Publisher Copyright: © 2022 The Author(s)
PY - 2022/12/12
Y1 - 2022/12/12
N2 - Ixodes ricinus and Ixodes scapularis are the main vectors for the causative agents of Lyme borreliosis and a wide range of other pathogens. Repeated tick-bites are known to lead to tick rejection; a phenomenon designated as tick immunity. Tick immunity is mainly directed against tick salivary gland proteins (TSGPs) and has been shown to partially protect against experimental Lyme borreliosis. TSGPs recognized by antibodies from tick immune animals could therefore be interesting candidates for an anti-tick vaccine, which might also block pathogen transmission. To identify conserved Ixodes TSGPs that could serve as a universal anti-tick vaccine in both Europe and the US, a Yeast Surface Display containing salivary gland genes of nymphal I. ricinus expressed at 24, 48 and 72 h into tick feeding was probed with either sera from rabbits repeatedly exposed for 24 h to I. ricinus nymphal ticks and/or sera from rabbits immune to I. scapularis. Thus, we identified thirteen TSGP vaccine candidates, of which ten were secreted. For vaccination studies in rabbits, we selected six secreted TSGPs, five full length and one conserved peptide. None of these proteins hampered tick feeding. In contrast, vaccination of guinea pigs with four non-secreted TSGPs – two from the current and two from a previous human immunoscreening - did significantly reduce tick attachment and feeding. Therefore, non-secreted TSGPs appear to be involved in the development of tick immunity and are interesting candidates for an anti-tick vaccine.
AB - Ixodes ricinus and Ixodes scapularis are the main vectors for the causative agents of Lyme borreliosis and a wide range of other pathogens. Repeated tick-bites are known to lead to tick rejection; a phenomenon designated as tick immunity. Tick immunity is mainly directed against tick salivary gland proteins (TSGPs) and has been shown to partially protect against experimental Lyme borreliosis. TSGPs recognized by antibodies from tick immune animals could therefore be interesting candidates for an anti-tick vaccine, which might also block pathogen transmission. To identify conserved Ixodes TSGPs that could serve as a universal anti-tick vaccine in both Europe and the US, a Yeast Surface Display containing salivary gland genes of nymphal I. ricinus expressed at 24, 48 and 72 h into tick feeding was probed with either sera from rabbits repeatedly exposed for 24 h to I. ricinus nymphal ticks and/or sera from rabbits immune to I. scapularis. Thus, we identified thirteen TSGP vaccine candidates, of which ten were secreted. For vaccination studies in rabbits, we selected six secreted TSGPs, five full length and one conserved peptide. None of these proteins hampered tick feeding. In contrast, vaccination of guinea pigs with four non-secreted TSGPs – two from the current and two from a previous human immunoscreening - did significantly reduce tick attachment and feeding. Therefore, non-secreted TSGPs appear to be involved in the development of tick immunity and are interesting candidates for an anti-tick vaccine.
KW - Anti-tick vaccine
KW - Borrelia
KW - Conserved
KW - Ixodes
KW - Tick salivary gland proteins
KW - Yeast surface display
UR - http://www.scopus.com/inward/record.url?scp=85142714796&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.vaccine.2022.10.032
DO - https://doi.org/10.1016/j.vaccine.2022.10.032
M3 - Article
C2 - 36357287
SN - 0264-410X
VL - 40
SP - 7593
EP - 7603
JO - Vaccine
JF - Vaccine
IS - 52
ER -